+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID07804615

Evaluating the Effects, Safety, and Pharmacokinetics of VIM0423 in Adults with Parkinsons Disease Tremor Not Responsive to Dopaminergic Therapy

Led by Vima Therapeutics · Updated on 2026-10-27

80

Participants Needed

30

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug VIM0423 in adults with Parkinsons disease who experience tremors that do not respond well to dopaminergic therapy. The study aims to determine if VIM0423 improves tremor symptoms, is well tolerated, and enhances daily function and quality of life. This Phase 2, multicenter, randomized, placebo-controlled trial will enroll up to 80 participants with Parkinsons tremor, a symptom that affects many and is often the most troubling for patients. Participants are divided into two groups Cohort 1 includes those on stable dopaminergic therapy with residual tremor, and Cohort 2 includes those who have never used dopaminergic therapies. Both cohorts are randomized to receive either VIM0423 or matching placebo, with doses up to five pills once daily for seven weeks. The study is triple-blinded, meaning neither participants nor investigators know the assigned treatment. The total participation lasts up to 12 weeks, including screening, treatment with tapering, and safety follow-up. During the study, participants attend six in-person visits for assessments including clinical evaluations, lab tests, and EKGs. They will wear a device to monitor tremor and complete self-assessments of tremor impact on daily activities. The primary outcome is change in Parkinsons disease symptoms measured by the Movement Disorder Society Unified Parkinsons Disease Rating Scale from baseline to Week 6. Secondary measures include clinician and patient global impressions, tremor-related daily living scales, and sleep assessments. Safety and adverse events are closely monitored throughout.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here